INNOVATION IN RENAL TRANSPLANT AND AUTOINMUNE CONDITIONS TO CREATE A NEW PROFITABLE MARKET
Biohope is a commercial stage R&D company dedicated to the development of precision medicine IVD tools for chronic inflammatory conditions. Biohope received funding through the European Commission’s H2020 program, and employs 17 professionals in R&D, IT, Medical Affairs, Financial, Legal, Quality Control and BD&L.
Our lead product, IMMUNOBIOGRAM®, is a novel, patented in vitro diagnostic device which allows the personalization of immunosuppressive therapy to improve health outcomes and reduce health care costs.
A national clinical study and an International Trial in kidney transplantation with over 200 patients, have demonstrated the benefits of the IMMUNOBIOGRAM® .
In addition to its use for transplanted patients, the technology is being adapted for other inflammatory /autoimmune conditions, such as Liver Transplant, Lupus, and Rheumatoid Arthritis.
Biohope is seeking investment/partner(s) to commercialize the IMMUNOBIOGRAM® in Renal Transplant and fully develop the IMMUNOBIOGRAM®– in other autoimmune conditions
FIVE REASONS TO PARTNER WITH US
Market: Large, growing, profitable and unsatisfied market with clear advantages over competitors.
Product: Breakthrough precision medicine product adding value to physicians, patients and payers.
Business Model: Solid business model with strong focus on core activities to achieve business and financial.
Scientific Community: High level of scientific partners and Health Care Institutions.
Management Team: Strong professional and highly committed Team.